OR WAIT null SECS
While biopharma companies will pay more than $3 million to file an NDA or BLA application during fiscal year 2022, new fees for generic drugs will see modest or no increases and those for biosimilars may drop or hold even.
Biopharmaceutical companies will pay more than $3 million to file an application seeking FDA approval of a new drug (NDA) or biologic (BLA) during fiscal year 2022. This record charge to evaluate new drugs and biologics reflects agency analysis of additional personnel and resources needed to process its growing workload1,2 The annual program fee paid by each manufacturer with marketed prescription drugs holds fairly even at about $370,000. And while the actual increase in the application fee is not that much, passing the $3 million mark has drawn attention—and further concern about FDA’s overdependence on revenue from regulated industry.
At the same time, new fees for generic drugs, biosimilars, medical devices, animal drugs and outsourcing facilities (drug compounders) will see modest—or no—increases. Most notable is that fees for developing and filing applications for new biosimilars will drop or hold even.3 With program reserves higher than expected, CDER halved fees for establishing, maintaining and reactivating biosimilar product development (BPD) programs. Application fees for biosimilars remain at $1.7 million, and annual program fees at slightly more than $300,000.
Similarly, generic drug fees remain fairly flat. Filing an abbreviated new drug application (ANDA) will cost $226,000, while the annual program fee stays at about $1.5 million. Fees for each manufacturing facility will range from $42,000 for a domestic API producer to $210,000 for a foreign manufacturer of finished dosage forms.4
These varying fees for applications, facilities and annual program oversight for medical products reflect the range in FDA oversight of differing R&D and manufacturing operations. Sponsors usually submit fairly few NDAs a year, and thus pay high rates for those, compared to the program fee. But as generic drug makers often file multiple ANDAs and maintain many facilities, the individual fees are lower, compared to a relatively higher annual program fee, which varies with company size. And because FDA provides considerable support and advice to biosimilar makers during product development, that fee program begins prior to filing an application; the application fee is less than for an NDA but much more than for an ANDA.
FDA bases its rates for FY 2022 on projections that sponsors will submit 161 NDAs/BLAs to CDER, about 1350 efficacy and labeling supplements, and 2388 manufacturing supplements. The program will fund the cost of holding some 4500 meetings with sponsors and oversee more than 9,500 active INDs. Workload increases at both CDER and CBER altogether will require a $27 million increase in PDUFA fees to reach $1.149 billion in FY 2022.
The fees set for fiscal year 2022 (begins Oct. 1, 2021) are noteworthy, as their announcement comes as FDA and industry are finalizing agreements for new five-year user fee programs. These need to be reauthorized by Congress early next year in order to start collecting new fees Oct. 1 2022. PDUFA application fees are slated to increase to $4 million over the next five-year fee program, which will be specified along with multiple other revisions in new “commitment letters” that FDA has negotiated with industry for its various user fee programs (PDUFA VII, BsUFA III, GDUFA III). The process of enacting legislation to reauthorize the fees every five years provides members of Congress with an opportunity to add a broad range of policy and program requirements that often impose notable changes on FDA operations and priorities.